BRCA1 tumor suppression nullified by cyclin D1, Researchers find

(I-Newswire) August 14, 2005 - For about a decade, scientists have recognized that many cases of hereditary breast cancer result from a mutation of a specific gene called BRCA1, which, in its normal state, helps keep tumor formation in check. About five to 10 percent of breast cancer cases arise from these genetic miscues, about half of which are linked to the abnormal functioning of BRCA1.

But now scientists have discovered that a protein called cyclin D1, grossly overproduced in about half of all cases of breast cancer, can also disrupt BRCA1's normal role as a cancer inhibitor. They found that because cyclin D1 binds to the same estrogen receptor as does BRCA1, when the cell is flooded with cyclin D1, BRCA1 is unable to activate a pathway that stops cancer development.

The results reaffirm cyclin D1 as a candidate target for molecular therapeutic control of breast tumor development.

"We've previously shown that if you have a gene therapy vector that blocks cyclin D1 in breast tumors, you can block the growth of those tumors," said Richard Pestell, M.D., Ph.D., director of the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center and senior author of the paper published in the August 1 issue of Cancer Research.

Also part of the Georgetown University research team were Chenguang Wang, Ph.D., assistant professor at the Lombardi Comprehensive Cancer Center and the lead author of the article, and Georgetown Professor of Oncology Eliot M. Rosen, a co-investigator on the study, which was funded in part by a grant from the Department of Defense. Participating in the research from the Georgetown oncology department were Saijun Fan, Zhiping Li, Maofu Fu, Mahadev Rao, Yongxian Ma, and Chris Albanese.

This paper, Pestell said, identifies the mechanism by which cyclin D1 nullifies one activity of the tumor suppressor BRCA1.

"Cyclin D1 is a collaborative oncogene and is sufficient for the induction of breast tumorogenesis in transgenic mice," he said. "This protein blocks the functional activity of the BRCA1 tumor suppressor. The science reported in this paper describes an important oncogene/tumor suppressor interaction."

The tumor-promoting action of various oncogenic sources upregulating expression of cyclin D1 converge at the common binding site on the estrogen receptor alpha (ERa) that is shared by both cyclin D1 and BRCA1. This research builds on a major discovery by the laboratory by Dr. Rosen, showing that BRCA1 interacts with, and inhibits the activity of ERa, the protein that transduces the growth signal of estrogen.

"This may help explain why the cyclin D1 gene and the BRCA1 gene are important primarily in hormone responsive cancers," Pestell said. "The interaction occurs at the level of the ERa hormone receptor."

Cyclin D1 is a protein produced by cells and routinely functions in events that promote cell division. In cancer, cyclin D1 is regulated and abundantly overexpressed by a number of factors that promote tumor growth, such as the oncogenes ErB2, src, and ras. In more than half of human patients with breast cancer, tumor cells produce as much as eight times the amount of cyclin D than healthy breast cells.

Cyclin D1 interferes with BRCA1 function because the two proteins both bind to the same spot on ERa, an important protein that governs cell proliferation properties in both healthy and cancerous cells. In healthy cells, BRCA1 binds to ERa to restrain and control estrogen-target genes that promote cell division. In cancer cells, however, cyclin D1 occupies the binding site on the ERa to promote proliferation. The abundance of cyclin D1 pre-empts BRCA1 binding to the estrogen receptor and negates the tumor suppressor role of the BRCA1 gene product.

In addition to their Georgetown research colleagues, Wang and Pestell conducted their research in concert with Michael Lisanti, Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York, N.Y.; Benita Katzenellenbogen, Departments of Molecular and Integrative Physiology and Cell and Structural Biology, University of Illinois and College of Medicine, Urbana, Ill.; Peter J. Kushner, Metabolic Research Unit, University of California-San Francisco School of Medicine, San Francisco, Calif.; and Barbara Weber, Department of Molecular Genetics, University of Pennsylvania, Philadelphia, Pa.

A link to the article is available here: cancerres.aacrjournals.org/current.shtml Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through our partnership with MedStar Health). Our mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis--or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing and Health Studies, both nationally ranked, and the world renowned Lombardi Comprehensive Cancer Center.

Laura Cavender
lsc6@georgetown.edu
202-687-5100
Georgetown University Medical Center
gumc.georgetown.edu

Company Contact Information